La Maddalena S.p.A.
- Address
- Via San Lorenzo 312 D, 90146 Palermo, Italy
La Maddalena S.p.A. - Advanced Oncology Research Center
La Maddalena S.p.A. is a specialized clinical research institution focused on advancing precision oncology and targeted cancer therapies. The center demonstrates particular expertise in molecularly-guided treatment strategies and novel therapeutic combinations across multiple cancer types, with emphasis on personalized medicine approaches based on genetic biomarkers and molecular profiling.
- Non-Small Cell Lung Cancer (NSCLC) with EGFR mutations, MET deregulation, and PD-L1 high expression
- Metastatic Renal Cell Carcinoma (mRCC) including oligometastatic disease and immunotherapy combinations
- Hematologic malignancies including Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Metastatic Colorectal Cancer (mCRC) with RAS/BRAF biomarker stratification using liquid biopsy
The center conducts sophisticated Phase II and Phase III trials investigating chemotherapy-free regimens, immunotherapy combinations, and targeted kinase inhibitors. Their research portfolio includes studies on adjuvant and perioperative strategies, optimal drug sequencing, and biomarker-driven treatment selection. Notable areas of investigation include PARP inhibitors for BRCA-mutated breast cancer, checkpoint inhibitor combinations with bevacizumab or axitinib, and novel bispecific antibodies. The center also participates in cardiovascular research, specifically evaluating anticoagulation strategies for stress-induced atrial fibrillation, demonstrating a commitment to comprehensive patient care beyond oncology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 48 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 47 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Fondazione Ricerca Traslazionale3active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Fondazione Ricerca Traslazionale3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in La Maddalena S.p.A.
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Olaparib as Adjuvant Therapy in Germline BRCA1/2 Mutated High-Risk HER2-Negative Primary Breast Cancer: A Phase III Randomized Study | AstraZeneca AB | Phase III | Not Recruiting | Aug 2014 | — |
IMP list
lock Showing 1 of 48 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bevacizumab | 2 | Unknown | 2020-01-31 | 2024-12-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.